| Title : Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome - Zhang_2024_World.J.Diabetes_15_724 |
| Author(s) : Zhang GL , Liu Y , Liu YF , Huang XT , Tao Y , Chen ZH , Lai HL |
| Ref : World J Diabetes , 15 :724 , 2024 |
| Abstract : BACKGROUND: Diabetic cardiomyopathy (DCM), which is a complication of diabetes, poses a great threat to public health. Recent studies have confirmed the role of NLRP3 (NOD-like receptor protein 3) activation in DCM development through the inflammatory response. Teneligliptin is an oral hypoglycemic dipeptidyl peptidase-IV inhibitor used to treat diabetes. Teneligliptin has recently been reported to have anti-inflammatory and protective effects on myocardial cells. AIM: To examine the therapeutic effects of teneligliptin on DCM in diabetic mice. METHODS: Streptozotocin was administered to induce diabetes in mice, followed by treatment with 30 mg/kg teneligliptin. RESULTS: Marked increases in cardiomyocyte area and cardiac hypertrophy indicator heart weight/tibia length reductions in fractional shortening, ejection fraction, and heart rate; increases in creatine kinase-MB (CK-MB), aspartate transaminase (AST), and lactate dehydrogenase (LDH) levels; and upregulated NADPH oxidase 4 were observed in diabetic mice, all of which were significantly reversed by teneligliptin. Moreover, NLRP3 inflammasome activation and increased release of interleukin-1beta in diabetic mice were inhibited by teneligliptin. Primary mouse cardiomyocytes were treated with high glucose (30 mmol/L) with or without teneligliptin (2.5 or 5 microM) for 24 h. NLRP3 inflammasome activation. Increases in CK-MB, AST, and LDH levels in glucose-stimulated cardiomyocytes were markedly inhibited by teneligliptin, and AMP (p-adenosine 5'-monophosphate)-p-AMPK (activated protein kinase) levels were increased. Furthermore, the beneficial effects of teneligliptin on hyperglycaemia-induced cardiomyocytes were abolished by the AMPK signaling inhibitor compound C. CONCLUSION: Overall, teneligliptin mitigated DCM by mitigating activation of the NLRP3 inflammasome. |
| ESTHER : Zhang_2024_World.J.Diabetes_15_724 |
| PubMedSearch : Zhang_2024_World.J.Diabetes_15_724 |
| PubMedID: 38680706 |
Zhang GL, Liu Y, Liu YF, Huang XT, Tao Y, Chen ZH, Lai HL (2024)
Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome
World J Diabetes
15 :724
Zhang GL, Liu Y, Liu YF, Huang XT, Tao Y, Chen ZH, Lai HL (2024)
World J Diabetes
15 :724